idiopathic pulmonary fibrosis Archive — Page 1 of 1

October 20, 2022

New target for lung fibrosis

Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.

By Leigh MacMillan
March 27, 2019

VUMC and TGen receive $6.1 million in grants to study deadly lung disease

Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.

By Nancy Humphrey
April 5, 2018

Lung diseases share molecular signature

Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention.

By Leigh MacMillan
February 1, 2018

Study tracks therapy to slow idiopathic pulmonary fibrosis

Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.

By Nancy Humphrey
lungs
August 18, 2016

Major grant enhances pulmonary fibrosis research

Vanderbilt University Medical Center (VUMC) has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF).

By Kathy Whitney
January 15, 2015

New drugs approved to fight idiopathic pulmonary fibrosis

The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).

By Kathy Whitney